Single-domain antibody C7b for address delivery of nanoparticles to HER2-positive cancers-Reference-Cited by-同舟云学术

Single-domain antibody C7b for address delivery of nanoparticles to HER2-positive cancers

Published:2020 Issue:42 Volume:12 Page:21885-21894
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Vorotnikov Yuri A.¹²³^ORCID,Novikova Evgeniya D.¹²³,Solovieva Anastasiya O.⁴⁵³,Shanshin Daniil V.⁶⁷³,Tsygankova Alphiya R.¹²³^ORCID,Shcherbakov Dmitrii N.⁶⁷³⁸⁹,Efremova Olga A.⁴⁵³¹⁰¹¹^ORCID,Shestopalov Michael A.¹²³^ORCID

Affiliation:

1. Nikolaev Institute of Inorganic Chemistry SB RAS

2. 630090 Novosibirsk

3. Russian Federation

4. Research Institute of Clinical and Experimental Lymphology – branch of ICG SB RAS

5. 630060 Novosibirsk

6. State Research Center of Virology and Biotechnology VECTOR

7. Koltsovo

8. Russian-American Anti-Cancer Center

9. Altai State University

10. The Federal Research Center of Fundamental and Translational Medicine

11. 630117 Novosibirsk

Abstract

Single-domain antibody C7b is benchmarked against trastuzumab for targeted delivery of photoactive silica nanoparticles to a HER2 overexpressing cancer cell line and tissue.

Funder

Russian Science Foundation

Royal Society

Engineering and Physical Sciences Research Council

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2020/NR/D0NR04899B

Reference34 articles.

1. Therapeutic Antibodies Against Cancer